Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Langerhans cell histiocytosis that occurs during childhood.
Biomarker and diagnostic research for Langerhans cell histiocytosis specific to childhood has been reported in the published literature.
33 clinical trials registered, 18 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE3, 22 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07371182](https://clinicaltrials.gov/study/NCT07371182) |
Data assembled from 4 of 12 sources · Last updated Sep 21, 2026, 4:51 AM UTC
European rare disease database
Common questions about Langerhans cell histiocytosis specific to childhood
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions |
NA |
West China Second University Hospital |
RECRUITING |
[NCT07022834](https://clinicaltrials.gov/study/NCT07022834) | Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children | PHASE2 | West China Second University Hospital | RECRUITING |
[NCT07431060](https://clinicaltrials.gov/study/NCT07431060) | Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis | NA | West China Second University Hospital | RECRUITING |
[NCT07440290](https://clinicaltrials.gov/study/NCT07440290) | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. | PHASE2 | Cancer Research UK | RECRUITING |
[NCT04943224](https://clinicaltrials.gov/study/NCT04943224) | Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | PHASE2 | Anna Raciborska | RECRUITING |
133 publications have been identified in PubMed for Langerhans cell histiocytosis specific to childhood. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (32%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 51 | 38% |
Patient case studies | 42 | 32% |
Testing and diagnosis research | 11 | 8% |
Disease patterns and progression | 11 | 8% |
Other research | 6 | 5% |
New treatment approaches | 5 | 4% |
Clinical study results | 4 | 3% |
Laboratory research | 3 | 2% |
Santa-María López V (2026). [PMID: 41651751](https://pubmed.ncbi.nlm.nih.gov/41651751/). *An Pediatr (Engl Ed)*. [Review / Meta-Analysis]
Zhang K (2026). [PMID: 42214999](https://pubmed.ncbi.nlm.nih.gov/42214999/). *Int J Pediatr Otorhinolaryngol*. [Review / Meta-Analysis]
Benattia A (2026). [PMID: 41611252](https://pubmed.ncbi.nlm.nih.gov/41611252/). *Eur Respir J*. [Clinical Trial Publication]
Harari S (2026). [PMID: 42167770](https://pubmed.ncbi.nlm.nih.gov/42167770/). *Eur Respir J*. [Other]
Rech KL (2026). [PMID: 41651609](https://pubmed.ncbi.nlm.nih.gov/41651609/). *Surg Pathol Clin*. [Review / Meta-Analysis]
Chilingarashvili G (2026). [PMID: 41613828](https://pubmed.ncbi.nlm.nih.gov/41613828/). *Pulm Circ*. [Review / Meta-Analysis]
Keehan L (2026). [PMID: 41174928](https://pubmed.ncbi.nlm.nih.gov/41174928/). *Am J Med Genet A*. [Review / Meta-Analysis]
Wang W (2026). [PMID: 41823178](https://pubmed.ncbi.nlm.nih.gov/41823178/). *Pediatr Blood Cancer*. [Clinical Trial Publication]
Sathish K (2026). [PMID: 42130999](https://pubmed.ncbi.nlm.nih.gov/42130999/). *J Orthop Case Rep*. [Case Report / Case Series]
Atirattanachai G (2026). [PMID: 41546712](https://pubmed.ncbi.nlm.nih.gov/41546712/). *Ann Hematol*. [Diagnostic / Biomarker]
AI-curated news mentioning Langerhans cell histiocytosis specific to childhood
Updated Sep 18, 2026
A recent case report highlights the use of contrast-enhanced sonography for diagnosing Langerhans cell hyperplasia in children with isolated liver involvement. This study contributes to the understanding of imaging techniques in rare pediatric liver diseases.
A Canadian multicenter case series investigates Langerhans cell histiocytosis in adults, providing new insights into its clinical presentation and management. This study contributes to the understanding of this rare disease, which may inform future research and treatment strategies.
A recent study highlights the complexities of diagnosing multifocal Langerhans cell histiocytosis, particularly when it involves the thyroid and multiple organs. This research underscores the need for heightened awareness and improved diagnostic strategies for this rare condition.